News | June 23, 2026
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
Clearing 19 biologics for Europe market
Clearing 19 biologics for Europe market
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Pharma powerhouse names Cecile Guegan interim finance chief
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
